6318-64-5Relevant articles and documents
Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds
Gong, Grace Qun,Wang, Ke,Dai, Xin-Chuan,Zhou, Yan,Basnet, Rajesh,Chen, Yi,Yang, De-Hua,Lee, Woo-Jeong,Buchanan, Christina Maree,Flanagan, Jack Urquhart,Shepherd, Peter Robin,Chen, Ying,Wang, Ming-Wei
, p. 1902 - 1912 (2018/07/31)
The serum and glucocorticoid-regulated kinase (SGK) family has been implicated in the regulation of many cellular processes downstream of the PI3K pathway. It plays a crucial role in PI3K-mediated tumorigenesis, making it a potential therapeutic target for cancer. SGK family consists of three isoforms (SGK1, SGK2, and SGK3), which have high sequence homology in the kinase domain and similar substrate specificity with the AKT family. In order to identify novel compounds capable of inhibiting SGK3 activity, a high-throughput screening campaign against 50,400 small molecules was conducted using a fluorescence-based kinase assay that has a Z' factor above 0.5. It identified 15 hits (including nitrogen-containing aromatic, flavone, hydrazone, and naphthalene derivatives) with IC50 values in the low micromolar to sub-micromolar range. Four compounds with a similar scaffold (i.e., a hydrazone core) were selected for structural modification and 18 derivatives were synthesized. Molecular modeling was then used to investigate the structure-activity relationship (SAR) and potential protein–ligand interactions. As a result, a series of SGK inhibitors that are active against both SGK1 and SGK3 were developed and important functional groups that control their inhibitory activity identified.
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization
Zhao, Lele,Wang, Yingqing,Cao, Danyan,Chen, Tiantian,Wang, Qi,Li, Yanlian,Xu, Yechun,Zhang, Naixia,Wang, Xin,Chen, Danqi,Chen, Lin,Chen, Yue-Lei,Xia, Guangxin,Shi, Zhe,Liu, Yu-Chih,Lin, Yijyun,Miao, Zehong,Shen, Jingkang,Xiong, Bing
, p. 1281 - 1297 (2015/03/04)
The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 μM in FP binding assay and GI50 of 0.1-0.3 μM in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development.
N-acyl anilines, useful for gastro-enterological disorders
-
, (2008/06/13)
This invention relates to novel N-acyl anilines, to a process for their preparation and to pharmaceutical compositions containing them. The N-acyl anilines are obtained by condensing a substituted aniline with an aminolower alkyl carboxylic acid or a functional derivative thereof. The compounds of the invention have therapeutic utility namely in the gastro-enterologic field.